1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is €15.94 (+100.25%). The median is €15.94 (+100.25%).
| Buy |
2 |
| Hold |
2 |
| Sell |
0 |
News Go to news feed
P3 Health Partners beats Q2 expectations and raises full-year outlook
P3 Health Partners reported adjusted EPS of -$0.63 in the second quarter (expectation: -$2.01) and revenue of $386.3 million (expectation: $375.05 million). Adjusted EBITDA swung to $54 million versus a year-ago loss of $17 million, and management raised the full-year adjusted EBITDA guidance to $80–110 million. The stock jumped and reached $16.00 in after-hours trading; the company attributes the improvement to better cost control, favorable payer settlements, and operational efficiency. » More on de.investing.com
Financials
| (EUR) | Jun 2026 | |
|---|---|---|
| Revenue | 338.55M | 12.16% |
| Gross profit | 75.36M | 75.04% |
| Net profit | 6.52M | 137.76% |
| EBITDA | 40.15M | 552.59% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €26.02M |
Number of shares | 3.28M |
52-week high/low | €14.55 - €1.31 |
| Dividends | No |
Beta | 1.64 |
P/E ratio | -0.28 |
PEG ratio | -0.01 |
P/B ratio | 0.43 |
P/S ratio | 0.02 |
Company profile
| Name | P3 Health Partners Inc Class A |
| CEO | Aric Coffman |
| Employees | 320 |
Discover assets
Shareholders of P3 Health Partners Inc Class A also invest in the following assets
